Get the Stockscreener App
3.44
1.47%
+0.05
Anavex Life Sciences Corporation stock is currently priced at $3.44, with a 24-hour trading volume of 425.92K.
It has seen a +1.47% increased in the last 24 hours and a -28.93% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.37 pivot point. If it approaches the $3.49 resistance level, significant changes may occur.
Previous Close:
$3.39
Open:
$3.4
24h Volume:
425.92K
Market Cap:
$281.24M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-5.2121
EPS:
-0.66
Net Cash Flow:
$-29.31M
1W Performance:
-8.99%
1M Performance:
-28.93%
6M Performance:
-38.79%
1Y Performance:
-58.25%
1D Range:
$3.37
$3.48
52W Range:
$3.25
$10.45
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
51 West 52nd Street, 7th Floor, New York
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
GlobeNewswire Inc.
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
GlobeNewswire Inc.
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
GlobeNewswire Inc.
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
GlobeNewswire Inc.
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
Zacks Investment Research
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Anavex Life Sciences Corporation (AVXL) Net Income 2024
AVXL net income (TTM) was -$43.16 million for the quarter ending December 31, 2023, a +13.81% increase year-over-year.
Anavex Life Sciences Corporation (AVXL) Cash Flow 2024
AVXL recorded a free cash flow (TTM) of -$29.31 million for the quarter ending December 31, 2023, a -10.47% decrease year-over-year.
Anavex Life Sciences Corporation (AVXL) Earnings per Share 2024
AVXL earnings per share (TTM) was -$0.55 for the quarter ending December 31, 2023, a +15.38% growth year-over-year.
About Anavex Life Sciences Corporation
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
0.85%
3.20%
Cap:
|
Volume (24h):